全文获取类型
收费全文 | 51958篇 |
免费 | 7360篇 |
国内免费 | 1169篇 |
专业分类
耳鼻咽喉 | 404篇 |
儿科学 | 1306篇 |
妇产科学 | 1404篇 |
基础医学 | 5424篇 |
口腔科学 | 232篇 |
临床医学 | 4771篇 |
内科学 | 3376篇 |
皮肤病学 | 280篇 |
神经病学 | 920篇 |
特种医学 | 1827篇 |
外国民族医学 | 77篇 |
外科学 | 5770篇 |
综合类 | 5817篇 |
现状与发展 | 8篇 |
一般理论 | 1篇 |
预防医学 | 3972篇 |
眼科学 | 534篇 |
药学 | 3825篇 |
34篇 | |
中国医学 | 980篇 |
肿瘤学 | 19525篇 |
出版年
2024年 | 118篇 |
2023年 | 940篇 |
2022年 | 1239篇 |
2021年 | 2715篇 |
2020年 | 2560篇 |
2019年 | 2366篇 |
2018年 | 2203篇 |
2017年 | 2262篇 |
2016年 | 2461篇 |
2015年 | 2756篇 |
2014年 | 3585篇 |
2013年 | 4332篇 |
2012年 | 2984篇 |
2011年 | 3164篇 |
2010年 | 2458篇 |
2009年 | 2338篇 |
2008年 | 2363篇 |
2007年 | 2438篇 |
2006年 | 2333篇 |
2005年 | 2078篇 |
2004年 | 1720篇 |
2003年 | 1659篇 |
2002年 | 1323篇 |
2001年 | 1186篇 |
2000年 | 924篇 |
1999年 | 837篇 |
1998年 | 675篇 |
1997年 | 648篇 |
1996年 | 517篇 |
1995年 | 455篇 |
1994年 | 359篇 |
1993年 | 308篇 |
1992年 | 287篇 |
1991年 | 252篇 |
1990年 | 203篇 |
1989年 | 165篇 |
1988年 | 167篇 |
1987年 | 148篇 |
1986年 | 135篇 |
1985年 | 171篇 |
1984年 | 123篇 |
1983年 | 89篇 |
1982年 | 105篇 |
1981年 | 108篇 |
1980年 | 56篇 |
1979年 | 50篇 |
1978年 | 40篇 |
1977年 | 27篇 |
1976年 | 26篇 |
1975年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
31.
32.
33.
ObjectiveThis study used a prospective cohort study to observe the effect of triple-negative breast cancer on the 2-year disease-free survival rate with or without “TCM formula”.MethodsFrom November 1 st, 2016, the first patient was enrolled in the cohort study. A total of 356 patients were enrolled on January 30, 2019. Among them, 154 cases were followed up for 2 years. During the follow-up, there were 6 cases of shedding, so 6 cases were affected. A total of 148 cases were included in the analysis, including 73 in the exposed group and 75 in the non-exposed group. The exposed group was given “TCM formula” on the basis of standardized treatment, and the non-exposed group was treated with simple triple-negative breast cancer. The two groups visited each of the three months. The interview included safety examination (hematology and imaging). The endpoint was the difference in 2-year invasive disease-free survival between the exposed and non-exposed groups and the safety of the “TCM formula”.ResultsThere were 6 cases of shedding during the experiment and the shedding rate was 3.9 %. The 2-year rate of invasive disease-free survival in the exposed team was 88.7 % and the non-exposed group was 82.5 %. Logistic multivariate regression analysis predicted that “TCM formula” could reduce the disease-related recurrence and metastasis rate by 11 % (OR = 0.89, 95 % CI 0.37−0.956, P<0.05). Through K–M survival analysis, TNBC patients with age ≤35 years and regional lymph node stage N1 may be the benefit group of “TCM formula”(P<0.05). During the study, the incidence of total adverse events was 8.2 % in the exposed group, mainly manifested as stomach discomfort, diarrhea, and hepatocyte damage.Conclusion1. In the exposed group, the two-year rate of invasive disease-free survival increased by 6.2 % compared with the non-exposed group(P>0.05). 2. According to K–M survival analysis, TNBC patients with age ≤35 years and regional lymph node metastasis to N1 may be potential beneficiaries of “TCM formula”. 3. “TCM Formula” is safe and tolerable to most patients. 相似文献
34.
35.
Sweeka Alexander Gurjeet Dulku Sharbell Hashoul Donna B Taylor 《Journal of Medical Imaging and Radiation Oncology》2019,63(4):473-478
Contrast‐enhanced spectral mammography (CESM) has a number of uses including the work‐up of inconclusive findings on mammography, assessment of breast symptoms, cancer staging, evaluation of response to neoadjuvant chemotherapy and recently as an alternative to magnetic resonance imaging (MRI) in high‐risk screening. CESM can be swiftly incorporated into the workflow of busy breast clinics. We share our experiences with CESM at a large breast assessment centre in Western Australia. 相似文献
36.
《European journal of surgical oncology》2019,45(10):1812-1816
ObjectivesMeshes/matrices are commonly used in immediate breast reconstruction. There are few studies comparing biological and synthetic meshes and it is unknown what type of mesh gives the best long-term results. The aim of this study was to compare long-term health-related quality of life (HrQoL) and patient satisfaction in implant-based immediate breast reconstruction with a biological mesh (Surgisis®) with that of patients reconstructed with a synthetic mesh (TIGR ® Matrix Surgical Mesh).Material and methodsBoth cohorts were prospectively included and consecutively operated. Clinical data was collected. HrQoL was evaluated with EuroQoL-5 dimension – 3 levels questionnaire (EQ-5D-3L) and the Hospital Anxiety and Depression Scale (HADS) and the Breast-Q.Results and conclusionSeventy-one patients were operated on in the biological group and 49 in the synthetic group. The response rates were 75 and 84 per cent, respectively. Mean follow-up time was 74 months and 23 months, respectively. There were no statistical differences in satisfaction and quality of life between the two groups. Complications and radiation seem to lead to a lower satisfaction. Our findings could indicate that biological and synthetic meshes give an equal long-term result as regards patients’ perceived quality of life. 相似文献
37.
38.
Breast Elastography: How to Perform and Integrate Into a “Best-Practice” Patient Treatment Algorithm
Breast elastography has been available for more than 15 years but is not widely incorporated into clinical practice. Many publications report extremely high accuracy for various breast elastographic techniques. However, results in the literature are extremely variable. This variability is most likely due to variations in technique, a relatively steep learning curve, and variability in methods between vendors. This article describes our protocol for performing breast elastography using both strain elastography and shear wave elastography, which produces high sensitivity and specificity. Additionally, we will describe the most commonly known false-positive and false-negative lesions as well as how to detect them. 相似文献
39.
《Drug discovery today》2022,27(6):1733-1742
Compounds that exhibit assay interference or undesirable mechanisms of bioactivity are routinely encountered in assays at various stages of drug discovery. We observed that assays for the investigation of thiol-reactive and redox-active compounds have not been collected in a comprehensive review. Here, we review these assays and subject them to experimental optimization to improve their reliability. We demonstrate the usefulness of our assay cascade by assaying a library of bioactive compounds, chemical probes, and a set of approved drugs. These high-throughput assays should complement the array of wet-lab and in silico assays during the initial stages of hit discovery campaigns to pursue only hit compounds with tractable mechanisms of action. 相似文献
40.
Li Sun Zia Sadique Isabel dos-Santos-Silva Li Yang Rosa Legood 《International journal of cancer. Journal international du cancer》2019,144(10):2596-2604
In low and middle-income countries mammographic breast cancer screening is prohibitively expensive and a cheaper alternative option is to use ultrasound as the primary screening test. In 2009, China launched a breast cancer screening programme for rural women aged 35–64 years with clinical breast examination coupled with ultrasound as the primary tool. Our study aimed to analyse the cost-effectiveness of breast screening compared to no screening among Chinese rural women. We developed a Markov model to estimate the lifetime costs and effects for rural women aged 35 years from a societal perspective. Asymptomatic women in the intervention arm were screened every 3 years before age 64 years. Breast cancer in the non-screening arm can only be diagnosed on presentation of symptoms. Parameter uncertainty was explored using one-way and probabilistic sensitivity analyses. Compared to no screening, breast cancer screening cost $186.7 more and led to a loss of 0.20 quality-adjusted life years (QALYs). Breast screening was more expensive and did harm to health among rural women with an incremental cost-effectiveness ratio (ICER) of $-916/QALY. The sensitivity analysis identified utility loss from false positives as the factor that most influenced the results, but this did not affect the conclusions. In a rural setting with such low breast cancer incidence, screening for asymptomatic disease is not cost-effective with current screening tools. Priority should be given to ensure that symptomatic women have proper access to diagnosis and treatment at an early stage as this will lead to mortality reductions without the usual screening harms. 相似文献